Not All Prostate Cancer Mutations Created Equal for Olaparib Not All Prostate Cancer Mutations Created Equal for Olaparib

While the PARP inhibitor olaparib is the first of its kind to show an overall survival benefit in progressed metastatic prostate cancer, questions remain over its use in men without BRCA1/2 mutations.Medscape News UK
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news